Antitumor therapy based on cellular competition.

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Cancer gene therapy efficacy is limited by low tumor cell transduction rates.
• Cell competition, observed during tissue development, offers a potential mechanism to enhance gene therapy.
• A strategy combining selective advantage and suicide genes could improve tumor cell replacement and eradication.

Purpose of the Study:

• To investigate the use of cell competition to increase tumor cell transfection efficiency in cancer gene therapy.
• To develop a system where transfected cells gain a selective advantage and subsequently trigger tumor eradication.
• To evaluate the therapeutic potential of this strategy in vitro and in vivo.

Main Methods:

• Engineered colon cancer cells with a dihydrofolate reductase (DHFR)-thymidine kinase (TK) fusion gene for selective advantage and suicide.
• Utilized methotrexate (MTX) for positive selection (DHFR resistance) and ganciclovir (GCV) for negative selection (TK sensitivity).
• Performed in vitro and in vivo experiments with varying proportions of modified and parental cells, employing sequential MTX and GCV treatments.

Main Results:

• In vitro experiments demonstrated significant cell competition, with DHFR-TK transfected cells replacing parental cells from 0.1% to 90% within 35 days under MTX selection.
• Subsequent GCV treatment effectively eliminated the transfected cells.
• In vivo studies confirmed positive selection and demonstrated a statistically significant therapeutic effect.

Conclusions:

• Cell competition can be effectively leveraged to enhance tumor cell transfection in cancer gene therapy.
• The DHFR-TK fusion gene system allows for selective enrichment of transfected cells followed by their eradication.
• This strategy holds promise for improving the efficacy of cancer gene therapy, potentially leading to tumor eradication.